CN101612253B - Medicine composition used for treating pimple type urticaria - Google Patents
Medicine composition used for treating pimple type urticaria Download PDFInfo
- Publication number
- CN101612253B CN101612253B CN2009100673180A CN200910067318A CN101612253B CN 101612253 B CN101612253 B CN 101612253B CN 2009100673180 A CN2009100673180 A CN 2009100673180A CN 200910067318 A CN200910067318 A CN 200910067318A CN 101612253 B CN101612253 B CN 101612253B
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- medicine composition
- volatile oil
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine composition used for treating pimple type urticaria, belonging to the traditional Chinese medicine. The medicine composition comprises the following active substances according to parts by weight: 4 to 10 parts of skunk bugbane glucoside, 3 to 10 parts of cicada slough alcohol extract, 8 to 20 parts of betaine, 5 to 12 parts of rhizoma atractylodis volatile oil, 9 to 25 parts of linseed extract, 8 to 20 parts of angelica polysaccharide, 15 to 40 parts of rehmannia root extract, 2 to 7 parts of manchurian dutchmanspipe extract, 3 to 8 parts of herba schizonepetae volatile oil, 2 to 8 parts of gypsum and 2 to 10 parts of glycyrrhizic acid. The medicine composition is used for treating the pimple type urticaria and is also used for treating eczema and cutaneous pruritus.
Description
Technical field
The invention belongs to Chinese medicine, refer in particular to and be used to treat papular urticaria, also be used for eczema, skin pruritus.
Background technology
Papular urticaria is to cause mucocutaneous blood vessel that temporary inflammatory hyperemia takes place by various factors to ooze out with big quantity of fluid, cause the infringement of local edema property.This rash takes place rapidly and disappears, and has play to itch, and is that a kind of common skin is sick.Can cause by various endogenouss or ectogenic complicated factor.Common can reduce: 1. medicine: many medicines all can cause primary disease, like penicillin, furazolidone, sulfa drugs etc.Serum, vaccine etc. can be caused by allergy; Medicines such as morphine, cocaine, atropine can directly make mastocyte release tissue amine etc. cause.2. food: the fish, shrimp, Eriocheir sinensis, egg, milk etc. that contain specific proteins are common paathogenic factor.3. infect: bacterial infection, viral infection, fungal infection and parasitic infection or insect bite disease, like demodicid mite, flea, Cimex bedbug etc.4. inhalation (inhalatio): various pollen, dust etc.5. physics and chemical factor: like physical property and mechanical irritations such as hot and cold, daylight, friction and pressure, or some chemical substance gets into human body and causes.6. inherited genetic factors: like familial cold urticaria.7. Nervous and Mental Factors and endocrine change: psychentonia, act on a momentary impulse, menstruation, menopause, gestation etc.8. internal disease: lymphoma, cancerous protuberance, hyperthyroidism, rheumatism and rheumatoid arthritis, hyperlipemia, cholecystitis, nephritis, hepatopathy, diabetes etc.Motherland's medical science thinks that urticaria mainly is that wind, wet, pathogenic heat are accumulate due to the skin, or feels exogenous wind again because of heat in blood and fall ill, and therefore urticarial treatment should be main with pathogenic wind expelling heat clearing away, removing damp to relieve itching.
Doctor trained in Western medicine does not still have specific short to papular urticaria, eczema, skin pruritus at present; Adopt with antihistamine drug for oral administration more; The interim inhibition of corticosteroids medicine is many; Like oral western medicine, oral hormone, externally used solution lotion, Emulsion, mud cream, oil preparation, ointment, Emulsion, liniment, tincture and plaster etc.The corticosteroids medicine is used in long-time or heavy dose of external, can addiction cause drug dependence, and modal is that sb.'s illness took a favorable turn after the medication, in case after the drug withdrawal, the agents area primary affection increases the weight of.After again with hormone, above-mentioned sb.'s illness took a favorable turn or disappearance; As drug withdrawal again, knock-on property is sent out again, and more serious than in the past.Above-mentioned dermatosis is the commonly encountered diseases frequently-occurring disease, and long-term more can not giving on patient's the mind & body all brought great misery, has a strong impact on its work, study; Need curative effect rapid, effect is certain, has no side effect for this reason; Can prevent recurrence, but and the medicine taken of longer-term limit.
Summary of the invention
The present invention provides a kind of Chinese medicine composition, is used to treat diseases such as papular urticaria, eczema, skin pruritus.The technical scheme that the present invention takes is: include the active substance by following weight fraction ratio:
Cimicifugoside 4-10 part, Periostracum Cicadae ethanol extract 3-10 part, betanin 8-20 part, Rhzoma Atractylodis Lanceae volatile oil 5-12 part; Semen Lini extract 9-25 part, Radix Angelicae Sinensis polysaccharide 8-20 part, Radix Rehmanniae extract 15-40 part, Caulis Aristolochiae Manshuriensis extract 2-7 part; Herba Schizonepetae volatile oil 3-8 part, Gypsum Fibrosum 2-8 part, glycyrrhizic acid 2-10 part.
Be preferably:
7 parts of cimicifugosides, 6.5 parts of Periostracum Cicadae ethanol extract, 14 parts of betanins, 8.5 parts of Rhzoma Atractylodis Lanceae volatile oils, 17 parts of Semen Lini extracts, 14 parts of Radix Angelicae Sinensis polysaccharides, 27.5 parts of Radix Rehmanniae extracts, 4.5 parts of parts of Caulis Aristolochiae Manshuriensis extract, 5.5 parts of Herba Schizonepetae volatile oils, 5 parts in Gypsum Fibrosum, 6 parts of glycyrrhizic acids.
Above-mentioned various extracts can be through method for distilling acquisition arbitrarily in the prior art among the present invention.Be preferably:
Cimicifugoside: it is windproof an amount of to take by weighing raw material, and water decocts 1-3 time, adds 5-15 at every turn and doubly measures, decocted 0.5-3 hour, and filtration, merging filtrate, concentrated.
The Periostracum Cicadae ethanol extract: take by weighing the raw material Periostracum Cicadae in right amount with 6-15 times of ethanol of 1-3 each adding of 50%-90% alcohol reflux, decocted 0.5-3 hour, filter, merging filtrate concentrates.
Betanin: it is an amount of to take by weighing the raw material Cortex Lycii, and decocte with water 1-3 time adds 6-17 at every turn and doubly measures, and decocts 0.5-3 hour, filters, and merging filtrate concentrates.
Rhzoma Atractylodis Lanceae volatile oil: it is an amount of to take by weighing the raw material Rhizoma Atractylodis, with distilled water reflux, extract, 1-3 time, adds 7-15 times of distilled water at every turn and boils filtration in 1-3 hour, and merging filtrate concentrates.
Semen Lini extract: take by weighing the raw material Semen Lini in right amount with 8-18 times of ethanol of 1-3 each adding of 50%-90% alcohol reflux, decocted 0.5-3 hour, filter, merging filtrate concentrates.
Radix Angelicae Sinensis polysaccharide: it is an amount of to take by weighing the raw material Radix Angelicae Sinensis, with 70-95 ℃, the distilled water lixiviate of PH6.5-7.0 1-3 time, adds filtration in 15-30 times of flooding 1-3 hour at every turn, and merging filtrate concentrates.
Radix Rehmanniae extract: it is an amount of to take by weighing the raw material Radix Rehmanniae, and decocte with water 1-3 time adds 6-17 at every turn and doubly measures, and decocts 0.5-3 hour, filters, and merging filtrate concentrates.
Caulis Aristolochiae Manshuriensis extract: it is an amount of to take by weighing the raw material Caulis Aristolochiae Manshuriensis, and decocte with water 1-3 time adds 7-17 at every turn and doubly measures, and decocts 0.5-3 hour, filters, and merging filtrate concentrates.
Herba Schizonepetae volatile oil: it is an amount of to take by weighing the raw material Herba Schizonepetae, with distilled water reflux, extract, 1-3 time, adds 6-16 times of distilled water at every turn and boils filtration in 1-3 hour, and merging filtrate concentrates.
Glycyrrhizic acid: take by weighing the raw material Radix Glycyrrhizae in right amount with 7-18 times of ethanol of 1-3 each adding of 50%-90% alcohol reflux, decocted 0.5-3 hour, filter, merging filtrate concentrates.
The present invention can be mixed with medicament with one or more pharmaceutically acceptable carriers or adjuvant.
Above-mentioned pharmaceutically acceptable carrier is meant pharmaceutical carrier or the adjuvant that pharmaceutical field is conventional, for example: diluent, excipient and water etc., filler such as starch, dextrin, sucrose, mannitol, lactose, microcrystalline Cellulose etc.; Binding agent such as cellulose derivative, alginate, gelatin and polyvinylpyrrolidone; Wetting agent such as glycerol: disintegrating agent such as methyl starch sodium, hyprolose, cross-linked carboxymethyl cellulose, agar, calcium carbonate and sodium bicarbonate; Absorption enhancer such as quaternary ammonium compound; Surfactant such as hexadecanol, Tween 80, sodium lauryl sulphate; Alms bowl such as Kaolin and soap clay are carried in absorption; Lubricant such as Pulvis Talci, calcium stearate and magnesium, micropowder silica gel and Polyethylene Glycol etc.In medicament, can also contain other adjuvant such as flavouring agent, sweeting agent etc. in addition.
But the mode of medicament administered through oral, rectum or parenteral that the present invention processes is applied to the patient.Be used for when oral, can be made into conventional solid preparation such as tablet, capsule, powder, granule etc., process other liquid preparation of liquid preparation such as water or oil-suspending agent such as syrup, mixture, elixir etc.; When being used for parenteral, can be made into solution, powder pin, water or the oiliness suspending agent etc. of injection.The preferred form of the present invention is oral liquid, tablet, coated tablet, capsule, granule.
The present invention is used to treat papular urticaria, also is used for eczema, skin pruritus.The amount of application of the present invention and medicament thereof can be according to variations such as the type of route of administration, patient age, body weight, the disease of being treated and the orders of severity, and is oral, 1 years old with interior one day 1 bag; 1 to 4 years old one day 2 bags; 5 to 9 years old one day 3 bags; 10 to 14 years old one day 4 bags; More than 15 years old one day 6 bags, every bag of 10g divides and takes for 2-3 time.
The specific embodiment
Pharmacodynamic test of active extract of the present invention
1 experiment material
1.1 medicine medicine of the present invention hereinafter to be referred as wind-repellent itching-relieving granules, is provided by JiLin ZiXin Pharmacy Co., Ltd; Chlorphenamine, Hubei encyclopaedia Heng Di pharmaceutcal corporation, Ltd produces (051201) dextran (mw=20,000), and the Anhui Chaoyang Pharmaceutical Factory is produced (050816); Two hydrochloric acid histamines, Shanghai Inst. of Biochemistry, Chinese Academy of Sciences produces (9405146); Chemical plant, dimethyl sulfoxide (DMSO) Kingsoft, Shanghai produces (950405); DPT vaccine, Changchun Biological Products Institute, Ministry of Public Health produces (030201-1-4); Sodium cromoglicate, Qianjiang City, Hubei pharmaceutical factory produces (0408012); Azovan blue, Shanghai chemical reagent purchasing and supply station, hydrocortisone injection, Hubei Pharmaceutic Works produces (040306), xylene, chemical plant, the pool, East Lake produces (030723).
1.2 animal Kunming mouse, Wistar rat and Cavia porcellus male and female dual-purpose, regular grade is provided by Jilin University's Experimental Animal Center.
2 methods and result
2.1 effect to drug-induced animal skin pruritus
Get 50 mices, body weight 18-22g, male and female half and half, 10 every group are divided into 1 group of 5 groups of wind-repellent itching-relieving granules, 2 groups, 3 groups at random and are respectively 88g/kg, 44g/kg, 22g/kg (the contained crude drug amount of medicinal liquid); Chlorphenamine matched group dosage is 4mg/kg, and the blank group is given normal saline 20ml/kg; Each group is respectively at behind ig administration or the normal saline 30min, and iv dextran 1 .25mg/kg writes down the total degree of the outbreak of scratching where it itches in the 30min and continues total time.
Other get Cavia porcellus 50 body weight 300-400g grouping and administration or normal saline dosage the same before experiment 1h deduct right back breech and also use sand paper scratch mark, the about 2cm of area
2, after each organizes ig administration or normal saline 30min, with the 50 μ l of 0.05% 2 hydrochloric acid histamine; Smear scratch mark; Cavia porcellus is wiped the scratch mark action as not occurring licking in the 3min, and repaste is smeared primary structure amine, and so histamine's number of times and cumulative volume smeared in repetitive operation record till occurring.The above results is seen table 1, table 2.
Table 1 wind-repellent itching-relieving granules is to the influence
of dextran induced mice skin pruritus
With the blank ratio,
★ ★P＜0.01
The influence
that table 2 wind-repellent itching-relieving granules is scratched where it itches to guinea pig skin due to the histamine
With the blank ratio
★ ★P＜0.01,
★P＜0.05,
2.2 effect to rat passive cutaneous anaphylaxis, PCA of the same race
Get 5 of male rats, intramuscular injection 5% Ovum Gallus domesticus album normal saline 0.5ml, lumbar injection immunological adjuvant DPT vaccine 2 * 10 simultaneously
10Individual/only, the rat ovaserum of blood sampling in the socket of the eye, preparation behind the 12d.
Other gets 50 body weight 150-200g of rat, is divided into 5 groups at random, and wherein blank group, wind-repellent itching-relieving granules group medication and consumption are ditto said, and sodium cromoglicate matched group dosage is 25mg/kg.Each organizes every rat back subcutaneous injection through ovaserum 0.1ml of dilution in 1: 5 and gastric infusion respectively, every day gastric infusion once, continuous 3 times; After the last administration 1 hour; Be to carry out antigen challenge in 48 hours after the sensitization, in tail vein injection 5% Ovum Gallus domesticus album 0.5ml/100g and 1% azovan blue normal saline-acetone (3: the 7) mixed liquor, placed 24 hours; Get supernatant, measure OD value (OD) in the 610nm place with 721 spectrophotometers.The result shows; Wind-repellent itching-relieving granules all has the obvious suppression effect to passive cutaneous anaphylaxis, PCA of the same race for 1,2,3 groups, and the result sees table 3.
Table 3 wind-repellent itching-relieving granules is to the influence
of rat passive cutaneous anaphylaxis, PCA of the same race
With the blank ratio
★ ★P＜0.01,
★P＜0.05,
2.3 effect to the non-immunity contact urticaria
Get 50 of Cavia porcelluss, body weight 300-400g is divided into 5 groups at random, divides into groups and dosage experiment 1 together.After each organizes every Cavia porcellus gastric infusion 30min; Outside the wide two sides of auris dextra, be coated with 80% dimethyl sulfoxine (dehydrated alcohol preparation), 50 μ l; After this in 1 hour, 3 hours thickness with 4 points of vernier caliper measurement auricle; Obtain meansigma methods, deduct the outer meansigma methods that is coated with preceding 4 points of dimethyl sulfoxine, difference is a Cavia porcellus ear swelling value.The result shows that the big or middle dose groups of wind-repellent itching-relieving granules causes the right obvious suppression effect of Cavia porcellus ear swelling to dimethyl sulfoxine, and the result sees table 4.
Table 4 wind-repellent itching-relieving granules causes the influence
of Cavia porcellus ear swelling to dimethyl sulfoxine
With the blank ratio
★P＜0.05,
2.4 effect to the rat capillary permeability
Get 50 of rats, body weight 200-250g is divided into 5 groups at random; Each organizes dosage and method with experiment 1, and each organizes after every rat oral gavage administration 30 minutes, at rat back subcutaneous injection 1 μ g/ml histamine 0.1ml; The 1% azovan blue normal saline 4ml/kg of intravenous injection immediately put to death rat after 15 minutes, and the skin of back locus coeruleus is cut; Place 5ml normal saline-acetone (3: 7) mixed liquor, get supernatant after 24 hours and measure OD value (OD) in the 610nm place with 721 spectrophotometers.Experimental result shows that wind-repellent itching-relieving granules has certain inhibitory action to the capillary permeability increase due to the histamine, and is wherein more obvious with the big or middle dose groups of wind-repellent itching-relieving granules.The result sees table 5.
Table 5 wind-repellent itching-relieving granules is to the influence
of rat capillary permeability
With the blank ratio
★ ★P＜0.01,
★P＜0.05,
2.5 wind-repellent itching-relieving granules xylol induced mice ear swelling effect
Get 60 of mices, body weight 27-30 gram, male and female half and half; Be divided into 5 groups at random, 12 every group, wind-repellent itching-relieving granules group and blank group dosage and saline dosage, method are with experiment 1; Hydrocortisone group lumbar injection 0.5% hydrocortisone 40mg/kg, each organizes administration or saline are smeared mice left side ear with xylene 0.1ml after 30 minutes both sides, after the administration 15 minutes; Mice is put to death, cut two ears, use diameter to downcut the circular auricle of two ears as the card punch of 0.8mm; Weigh immediately, calculate the ear swelling rate.The result sees table 6.
The influence (n=12) of table 6 xylol induced mice ear swelling
With the blank ratio
★ ★P＜0.01
More than experiment shows that wind-repellent itching-relieving granules is inhibited to the skin pruritus of drug-induced animal.Infer that it has antihistamine effect.The vascular permeability increase that causes to the skin allergy of animal and to inflammatory mediator histamine, 5-hydroxy tryptamine is also inhibited, therefore can think that this medical instrument has anti-allergic effects.Dimethyl sulfoxine and xylene are caused that the inhibitory action of animal ear swelling shows that this medical instrument has anti-non-immune contact urticaria effect and antiinflammatory action.
Embodiment 1
Cimicifugoside 40g, Periostracum Cicadae ethanol extract 30g, betanin 80g, Rhzoma Atractylodis Lanceae volatile oil 50g, Semen Lini extract 90g, Radix Angelicae Sinensis polysaccharide 80g, Radix Rehmanniae extract 150g, Caulis Aristolochiae Manshuriensis extract 20g, Herba Schizonepetae volatile oil 30g, Gypsum Fibrosum 20g, glycyrrhizic acid 20g.
Add the conventional adjuvant of preparation tablet, process tablet by usual manner.
Embodiment 2
Cimicifugoside 70g, Periostracum Cicadae ethanol extract 65g, betanin 140g, Rhzoma Atractylodis Lanceae volatile oil 85g, Semen Lini extract 170g, Radix Angelicae Sinensis polysaccharide 140g, Radix Rehmanniae extract 275g, Caulis Aristolochiae Manshuriensis extract 45g part, Herba Schizonepetae volatile oil 55g, Gypsum Fibrosum 50g, glycyrrhizic acid 60g.
Add the conventional adjuvant of preparation granule, process granule 5000g, pack, every bag of 10g by usual manner.
Embodiment 3
Cimicifugoside 100g, Periostracum Cicadae ethanol extract 100g, betanin 200g, Rhzoma Atractylodis Lanceae volatile oil 120g, Semen Lini extract 250g, Radix Angelicae Sinensis polysaccharide 200g, Radix Rehmanniae extract 400g, Caulis Aristolochiae Manshuriensis extract 70g, Herba Schizonepetae volatile oil 80g, Gypsum Fibrosum 80g, glycyrrhizic acid 100g.
Add the conventional adjuvant of preparation capsule, process capsule by usual manner.
Claims (2)
1. pharmaceutical composition that is used to treat papular urticaria is characterized in that what it was made up of the active substance of following weight portion:
Cimicifugoside 4-10 part, Periostracum Cicadae ethanol extract 3-10 part, betanin 8-20 part, Rhzoma Atractylodis Lanceae volatile oil 5-12 part; Semen Lini extract 9-25 part, Radix Angelicae Sinensis polysaccharide 8-20 part, Radix Rehmanniae extract 15-40 part, Caulis Aristolochiae Manshuriensis extract 2-7 part; Herba Schizonepetae volatile oil 3-8 part, Gypsum Fibrosum 2-8 part, glycyrrhizic acid 2-10 part.
2. the pharmaceutical composition that is used to treat papular urticaria according to claim 1 is characterized in that what it was made up of the active substance of following weight portion:
7 parts of cimicifugosides, 6.5 parts of Periostracum Cicadae ethanol extract, 14 parts of betanins, 8.5 parts of Rhzoma Atractylodis Lanceae volatile oils, 17 parts of Semen Lini extracts, 14 parts of Radix Angelicae Sinensis polysaccharides, 27.5 parts of Radix Rehmanniae extracts, 4.5 parts of Caulis Aristolochiae Manshuriensis extracts, 5.5 parts of Herba Schizonepetae volatile oils, 5 parts in Gypsum Fibrosum, 6 parts of glycyrrhizic acids.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100673180A CN101612253B (en) | 2009-07-17 | 2009-07-17 | Medicine composition used for treating pimple type urticaria |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100673180A CN101612253B (en) | 2009-07-17 | 2009-07-17 | Medicine composition used for treating pimple type urticaria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101612253A CN101612253A (en) | 2009-12-30 |
| CN101612253B true CN101612253B (en) | 2012-02-01 |
Family
ID=41492261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100673180A Active CN101612253B (en) | 2009-07-17 | 2009-07-17 | Medicine composition used for treating pimple type urticaria |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101612253B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102973674B (en) * | 2012-11-22 | 2014-08-13 | 张继成 | Eczema eliminating capsule |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1362126A (en) * | 2001-01-04 | 2002-08-07 | 杨孟君 | Nano wind-evil dispelling and itch stopping medicine and its preparation |
| CN1824032A (en) * | 2005-12-27 | 2006-08-30 | 江西青春康源制药有限公司 | Wind dispersing itch relieving tablet and its preparation method |
| CN1895451A (en) * | 2006-06-23 | 2007-01-17 | 徐新盛 | Medicinal composition for treating hives and eczema and its preparation |
-
2009
- 2009-07-17 CN CN2009100673180A patent/CN101612253B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1362126A (en) * | 2001-01-04 | 2002-08-07 | 杨孟君 | Nano wind-evil dispelling and itch stopping medicine and its preparation |
| CN1824032A (en) * | 2005-12-27 | 2006-08-30 | 江西青春康源制药有限公司 | Wind dispersing itch relieving tablet and its preparation method |
| CN1895451A (en) * | 2006-06-23 | 2007-01-17 | 徐新盛 | Medicinal composition for treating hives and eczema and its preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101612253A (en) | 2009-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103341145B (en) | Traditional Chinese medicine for treating psoriasis and preparation method thereof | |
| CN102813801A (en) | Traditional Tibetan medicine for treating cough and preparation method thereof | |
| CN102716395B (en) | Traditional Chinese medicine spray for treating skin diseases | |
| CN101732668B (en) | Preparation method of Chinese medicinal composition for treating urinary system infection | |
| CN102716394A (en) | Medicine composition for treating skin diseases | |
| CN101069726B (en) | Chinese medicine preparation of expelling toxin by cooling and eliminating damp and removing stasis, preparing method and use | |
| CN101926815B (en) | Paeoniflorin and glycyrrhetinic acid composition and preparation method and application thereof | |
| CN101612253B (en) | Medicine composition used for treating pimple type urticaria | |
| CN105343350A (en) | Application of Erding granules in preparation of drugs for treating or preventing hyperuricemia and gout diseases | |
| CN103405494A (en) | Bauhinia championii n-butyl alcohol extract and preparation method and application thereof | |
| CN101264314A (en) | Medicaments assembly for clearing heat and detoxication, activating blood circulation and removing stasis, and diminishing inflammation and reducing pain | |
| CN101524407B (en) | Medicine composition for curing gynecologic diseases and preparation method thereof | |
| CN100455309C (en) | Compound Chinese medicinal preparation for treating gynecological inflammation and preparation method thereof | |
| CN100457147C (en) | Chinese medicine composition for treating climacteric metancholia for women and preparing method thereof | |
| CN104491418A (en) | Traditional Chinese medicinal preparation for treating ulcerative colitis | |
| CN101607009B (en) | Pharmaceutical composition for treating cold | |
| CN102688330A (en) | Biological Chinese medicine film and preparation method thereof | |
| CN101991678B (en) | Application of India madder root in preparing medicine for preventing and treating kidney disease | |
| CN105169009A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating viral influenza | |
| CN102284036A (en) | Gujinwan capsule and preparation method thereof | |
| CN100534482C (en) | Soft capsule for treating vascular headaehe | |
| CN101167779B (en) | Application of Lagotis glauca gaertn extract in preparing antiviral medicine | |
| CN107281416A (en) | A kind of preparation that urarthritis is treated containing long-nosed pit viper | |
| CN106166214A (en) | One treats tonsillitic Chinese medicine composition and preparation method thereof | |
| CN101623468B (en) | Medicine composition used for treating infection diseases of urinary system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine composition used for treating pimple type urticaria Effective date of registration: 20190318 Granted publication date: 20120201 Pledgee: Jilin rural commercial bank and Limited by Share Ltd Pledgor: Jilin Zixin Pharmaceutical Co., Ltd. Registration number: 2019220000006 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20210929 Granted publication date: 20120201 |
|
| PP01 | Preservation of patent right |